Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
LTR Pharma Limited ( (AU:LTP) ) has shared an announcement.
LTR Pharma has secured a prestigious podium presentation at the 2026 World Meeting on Sexual Medicine for Phase 1 data on its SPONTAN intranasal vardenafil spray, underscoring growing international scientific interest in its erectile dysfunction technology. The independently conducted, company-sponsored crossover study in healthy males showed SPONTAN achieved faster drug absorption, a notably shorter time to peak concentration and higher dose-normalised bioavailability than oral vardenafil tablets, with both formulations well tolerated. Management and investigators say these pharmacokinetic advantages could translate into quicker onset of action and greater treatment flexibility for patients seeking more spontaneous sexual activity, strengthening LTR Pharma’s positioning in the ED market and validating its intranasal platform to a global specialist audience.
More about LTR Pharma Limited
LTR Pharma is a commercial-stage pharmaceutical company focused on innovative therapies delivered via its proprietary intranasal drug-delivery platform. The company has commercialised rapid-acting treatments in Australia and is pursuing regulatory pathways in the US and other key markets. Its lead products, SPONTAN and ROXUS, are fast-acting intranasal sprays for erectile dysfunction, while pipeline candidate OROFLOW targets oesophageal motility disorders, underpinning a strategy to provide differentiated, patient-centric treatments for significant unmet medical needs.
Average Trading Volume: 377,054
Technical Sentiment Signal: Buy
Current Market Cap: A$118.1M
See more data about LTP stock on TipRanks’ Stock Analysis page.